This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kovach, J. S. Articles by O'Connell, M. J. Search for Related Content PubMed PubMed Citation Articles by Kovach, J. S. Articles by O'Connell, M. J.

Phase 1 Trial and Assay of Rubidazone (NSC 164011) in Patients with Advanced Solid Tumors¹

Divisions of Developmental Oncology Research [J. S. K., M. M. A., M. L. S.] and Medical Oncology [M. J. O.], Department of Oncology, Mayo Clinic, Rochester, Minnesota 55901

A new high-pressure liquid chromatographic method was developed for the simultaneous determination of rubidazone and daunorubicin in human plasma at concentrations as low as 60 ng/ml. Clinical toxicity and the stability of rubidazone were studied in nine patients with advanced solid tumors. Rubidazone was adminstered by i.v. infusion over 1 hr on a single day every 4 weeks. Moderate leukopenia was the dose-limiting toxicity in four of six patients treated at 150 mg sq/m. Assay of rubidazone in plasma samples obtained after administration of rubidazone showed that the drug was stable for at least 7 hr.

¹ Supported in part by National Cancer Institute Contract CM-53838 and National Cancer Institute Grant CA 15083 FF.

² To whom requests for reprints should be addressed.

Received 3/20/78. Accepted 12/ 1/78.